Trial Profile

An observational lead-in study for infigratinib in hypochondroplasia

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 28 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

24 Jun 2026 According to Kyowa Kirin media release, data from the trial will be presented at the International Congress of Childrens Bone Health (ICCBH) 2026, to be held in Montreal, Canada from June 27-30, 2026.
12 Jan 2026 According to a BridgeBio Pharma media release, Interim analysis from this trial were presented at at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.
12 Jan 2026 According to an BridgeBio Pharma media release,LPI (Last Patient In) achieved for the Phase 2 portion of ACCEL 2/3, the registrational study of infigratinib for children with hypochondroplasia.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com